Ethosuximide (All indications)

Major congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9782
R35034		 Bànhidy (Ethosuximide), 2011 Total congenital abnormalities throughout pregnancy case control unexposed, sick Adjustment: No Matched 4.13 [0.18;96.94] C 2/2   12/22 14 2
ref
Total 1 studies 4.13 [0.18;96.94] 14 2
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Ethosuximide), 2011Bànhidy, 2011 1 4.13[0.18; 96.94]1420%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: NA0.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 4.13[0.18; 96.94]142 -NABànhidy (Ethosuximide), 2011 1 Type of controls unexposed, sickunexposed, sick 4.13[0.18; 96.94]142 -NABànhidy (Ethosuximide), 2011 1 Tags Adjustment   - No  - No 4.13[0.18; 96.94]142 -NABànhidy (Ethosuximide), 2011 1 MatchedMatched 4.13[0.18; 96.94]142 -NABànhidy (Ethosuximide), 2011 1 All studiesAll studies 4.13[0.18; 96.94]142 -NABànhidy (Ethosuximide), 2011 10.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.14[0.59; 16.64]49,529210%NAKällén (Ethsuximide) (Controls unexposed, NOS) (Indications NOS), 2013 Samrén (Ethosuximide), 1999 2 unexposed, sick controlsunexposed, sick controls 3.60[0.88; 14.67]31250%NAVajda (Ethosuximide) (Controls unexposed, sick), 2019 Bànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls unexposed, sick), 2006 Kaaja (Ethosuximide), 2003 Dean (Ethosuximide), 2002 5 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.89[0.52; 6.92]153410%NAVajda (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2019 Tomson (Ethosuximide), 2018 Källén (Ethosuximide) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 40.510.01.0